drugset / Trial / NCT01632306

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

NCT01632306

Phase 1/2 Terminated 13 enrolled Eli Lilly and Company Mayo Clinic · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.

Timeline

Start
2013-03
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject LY2090314 Small molecule Intravenous
Subject Leucovorin Small molecule Intravenous
Subject Oxaliplatin Small molecule Intravenous
Subject Paclitaxel Small molecule 125 mg/m2 Intravenous
Subject fluorouracil Small molecule Intravenous